Skip to content

A clinical study based on PET-MRI to explore the correlation between rTMS intervention in depression and brain glucose metabolism and its mechanism

A clinical study based on PET-MRI to explore the correlation between rTMS intervention in depression and brain glucose metabolism and its mechanism

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101258
Enrollment
Unknown
Registered
2025-04-22
Start date
2024-12-10
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Treatment group:rTMS treatment
Control group:none

Sponsors

The First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Male aged 18-40; (2) Right-handed; (3) Patients with depression must meet the diagnostic criteria for depressive disorder in the American Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); (4) The 17 points of Hamilton Depression Scale (HDRS) for depressed patients must be greater than 17 points; (5) Healthy subjects must have no organic or mental illness; (6) Subjects who are willing to actively cooperate and sign informed consent after fully understanding the safety of rTMS and PET-MRI.

Exclusion criteria

Exclusion criteria: (1) Patients with metal implants, renal insufficiency, diabetes, or other PET-MRI scanning or transcranial magnetic stimulation treatment contraindications; (2) Patients who have taken glucocorticoids, ß-blockers, thiazide diuretics, fluoroquinolones, thyroid hormone preparations and other drugs affecting glucose metabolism in the past three months or suffer from other diseases that may affect brain glucose metabolism; (3) depression caused by bipolar disorder and other mental diseases; (4) Those who have been diagnosed with other mental disorders or have taken psychoactive drugs such as sedation and hypnosis in the past 3 months; (5) A history of any form of antidepressant treatment (including medication, physical and psychological therapy) within 1 month prior to enrollment; (6) have a history of organic brain disease; (7) Those with serious physical diseases; (8) Patients with psychotic symptoms requiring combined use of antipsychotic drugs; (9) Those with a high risk of suicide, or those who have committed suicide or serious self-injury and need emergency intervention (10) Planning pregnancy during the trial period; (11) Other circumstances that the researcher has determined are not suitable for the study.

Design outcomes

Primary

MeasureTime frame
Standard Uptake Value;Hamilton Depression Rating Scale;Montgomery-Asberg Depression Rating Scale;

Secondary

MeasureTime frame
Self-Rating Depression Scale;

Countries

China

Contacts

Public ContactWang Huaning

The First Affiliated Hospital of Air Force Military Medical University

13609161341@163.com+86 136 0916 1341

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026